ResMed Inc. (NYSE:RMD) Director Peter C. Farrell sold 20,000 shares of ResMed stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $83.53, for a total value of $1,670,600.00. Following the sale, the director now owns 314,800 shares of the company’s stock, valued at approximately $26,295,244. The transaction was disclosed in a document filed with the SEC, which is available at this link.

ResMed Inc. (NYSE RMD) opened at $83.06 on Friday. The firm has a market capitalization of $11,738.29, a PE ratio of 28.82, a PEG ratio of 1.84 and a beta of 0.79. ResMed Inc. has a 52 week low of $57.45 and a 52 week high of $87.81. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, meeting the consensus estimate of $0.66. The business had revenue of $523.66 million for the quarter, compared to analyst estimates of $506.08 million. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The company’s revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.62 EPS. sell-side analysts anticipate that ResMed Inc. will post 3 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be paid a $0.35 dividend. This represents a $1.40 annualized dividend and a dividend yield of 1.69%. The ex-dividend date is Wednesday, November 8th. ResMed’s dividend payout ratio is currently 56.68%.

TRADEMARK VIOLATION WARNING: “Insider Selling: ResMed Inc. (RMD) Director Sells $1,670,600.00 in Stock” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/insider-selling-resmed-inc-rmd-director-sells-1670600-00-in-stock/1694997.html.

Several research firms have commented on RMD. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a report on Thursday, October 12th. Citigroup Inc. upgraded ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday, August 2nd. BidaskClub cut ResMed from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. BMO Capital Markets lifted their price target on ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a report on Wednesday, August 2nd. Finally, Credit Suisse Group cut ResMed from an “outperform” rating to a “neutral” rating in a report on Tuesday, August 8th. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $67.57.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sawtooth Solutions LLC lifted its stake in shares of ResMed by 1.6% in the 2nd quarter. Sawtooth Solutions LLC now owns 3,167 shares of the medical equipment provider’s stock valued at $247,000 after purchasing an additional 49 shares in the last quarter. YorkBridge Wealth Partners LLC lifted its stake in shares of ResMed by 4.9% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 69 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in shares of ResMed by 2.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,489 shares of the medical equipment provider’s stock valued at $272,000 after purchasing an additional 82 shares in the last quarter. Atria Investments LLC lifted its stake in shares of ResMed by 3.9% in the 2nd quarter. Atria Investments LLC now owns 4,742 shares of the medical equipment provider’s stock valued at $369,000 after purchasing an additional 178 shares in the last quarter. Finally, Toronto Dominion Bank lifted its stake in shares of ResMed by 12.8% in the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after purchasing an additional 197 shares in the last quarter. 60.00% of the stock is currently owned by institutional investors and hedge funds.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.